FDA Clears MRI-Based AI Segmentation of Organs at Risk During Radiation Therapy
Capable of segmenting over 37 organs and structures in the head, neck and pelvis, the MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.
The Food and Drug Administration (FDA) has granted 510(k) clearance for MR Contour DL software, a deep learning-enabled magnetic resonance imaging (MRI) segmentation software that may facilitate enhanced radiation therapy treatment in the head, neck, and pelvis.
Currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference (May 2-6, 2025) in Vienna, Austria, the MR Contour DL software utilizes the soft tissue detail from MRI to provide artificial intelligence (AI)-powered segmentation of organs at risk, according to GE HealthCare, the developer of MR Contour DL.
Providing artificial intelligence (AI)-powered segmentation of organs at risk during radiation therapy, the newly FDA-cleared MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.
Leveraging standard 2D and 3D MRI, GE HealthCare noted the MR Contour DL software is capable of segmenting 37 organs and structures in the head, neck, and pelvis.
“We’re committed to advancing MR imaging capabilities in radiation therapy to deliver more accurate and precise care,” said Kelly Londy, the president and CEO of MR for GE HealthCare.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
